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Ø TP53, a tumor suppressor gene, incurs deletions or mutations 
in more than 50% of cancers.
Ø Cluster of Differentiation 276 (CD276), also known as B7 
Homolog 3 (B7-H3), is an immune checkpoint molecule. 
Ø Recent findings have shown that CD276 inhibits T cells to 
promote tumor proliferation and invasion. 
Ø Previous studies using CD276 as a target for immunotherapy 
have found promising anti-tumor effects with CD276 
antibodies.
Ø These anti-CD276 antibodies are currently undergoing 
clinical trials as immunotherapy agents.
Cell Lines: 
Ø Human prostate cancer cell lines: LNCaP, 22RV1, DU145, and 
PC3
Ø Mouse prostate cancer cell lines: PP7777 and DX1
Methods:
Ø Western blotting analysis
Ø Quantitative reverse transcription PCR
Ø Flow cytometry
Ø CRISPR/Cas9 and shRNA 
Ø Chromatin immunoprecipitation assay




▲ Figure 2. B7-H3 expression within human and mouse prostate cancer cells lines. 
(A) Flow cytometry analysis of B7-H3 expression in human prostate cancer cell lines. (B)
Flow cytometry data of B7-H3 expression in mouse prostate cancer cell lines.
▲ Figure 4. p53 knockout induces B7-H3 expression in LNCaP cell lines. (A) B7-H3 
expression observed through Western-blot analysis. (B) B7-H3 expression analyzed 
through flow cytometry. 
Figure 6. CD276 is downregulated 
in SP1 knockdown and p53 
knockout LNCaP cell lines. CD276 
expression analysis from real-time 
PCR data.
Figure 7. Transcription factor SP1 
binds to the promoter region of 
CD276. SP1-DNA sequence 





The immune checkpoint molecule CD276 was identified as a 
promising therapeutic candidate in prostate cancer. Our study 
demonstrated that the p53-SP1 axis is involved in the 
transcriptional regulation of CD276 in prostate cancer, suggesting 
the potential of immunotherapy targeting CD276 in p53-deficient 
cancers.  
▲ Figure 1. Immune checkpoint molecule alterations in patients with tumor 




Protein 1 (SP1) as a 
CD276 transcription 
factor involved in the p53 
pathway. Analysis of 
overlapping targets 
performed with the 
GeneCards database.
▲ Figure 9. Schematic of the interactions between CD276 and the p53-SP1 axis. 
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▲ Figure 8. SP1 shows greater 
transcription activity of CD276 for 
p53 deficient LNCaP cell lines. 
Transcription activity measured by 
Dual-luciferase reporter.








































































▲ Figure 3. B7-H3 expression is successfully knocked down in the PP7777 cell 
line. (A) B7-H3 expression level after shRNA transfection measured by Western-blot 
analysis. (B) B7-H3 expression level analyzed by flow cytometry. 
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